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The nasopharyngeal carcinoma (NPC) is a rare cancer 
with a high incidence in Southern Asia. Aim: to study the 
demographic, clinical, therapeutic, and prognostic factors of 
nasopharyngeal undifferentiated carcinoma in a reference 
service. Materials and methods: A retrospective study was 
made of 46 patients from January 1998 to August 2000. The 
patients had no previous treatment and did not present any 
evidence of synchronous tumors or distance metastases. 
Results: The age ranged from 14 to 78 years (mean = 
46 years); 35 (76%) patients were male. All patients were 
Caucasian or African-Brazilian. The onset of initial symptoms 
ranged from 1 to 48 months (mean = 7 months); 47% of 
the subjects smoked tobacco and 33% consumed alcoholic 
beverages. A lump in the neck was the most frequent 
symptom (34 patients). Twenty-two patients were clinically 
staged as T1/T2 and 24 patients as T3/T4; 24 patients were 
classified as N2, and 16 patients were staged as N3. Curative 
treatment consisted of radiotherapy and simultaneous 
chemotherapy in clinical stages III and IV. Of 27 patients that 
were monitored, 52% were alive with no evidence of disease 
after three years. Conclusion: All patients were in advanced 
clinical stages of the disease. The three-year disease-free 
survival rate was 52%.
Keywords: nasopharynx, carcinoma, chemotherapy, 
radiotherapy.
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INTRODUCTION
The incidence of nasopharyngeal carcinomas is rare 
in most of the world, except among Southeastern Asian 
populations, where it is one of the most frequent malig-
nancies. The highest incidences are seen in Alaskan and 
Greenland Eskimos and in Tunisia. The incidence remains 
high in Asians who have migrated to Western countries, 
compared to Caucasians.1,2 The etiology is still unknown. 
There are a few hypotheses, such as hereditary causes 
related to the HLA-A2 and HLA-Bsin2 viral genotypes, 
Epstein-Barr virus (EBV) infection, altered chromosomes 
and cultural factors such as increased amounts of fish and 
preserved food consumption that are rich in nitrosami-
des, known environmental carcinogens.3,4 The EBV may 
be found in tumor cells of patients by an RNA signal,5 
suggesting that peripheral blood may be investigated in 
endemic areas of this disease to detect anti-EBV antibodies. 
As opposed to other head and neck malignancies, smoking 
and alcohol consumption appear to be less important in 
the carcinogenesis of the aforementioned tumors. The 
prognosis of nasopharyngeal tumors depends on initial 
clinical staging and the histological subtypes.3
The incidence is distributed across all age groups, 
predominating at 50 and 60 years; males are affected more 
often. The incidence reaches 10 to 20 per 100 thousand 
male inhabitants and 5 to 10 per 100 thousand females in 
certain Southeastern regions of China.6
The diagnosis tends to be made when the disease 
is advanced, including signs and symptoms of invasion of 
the cranial base and cranial nerve involvement.7 Symptoms 
in early disease are rare, and may include nasal block, he-
adaches, deafness and otitis media. In later phases of the 
disease, invasion of adjacent structures to the cranial base 
affect more often the maxillary branch of the trigeminal 
nerve and the abducens nerve.7
The incidence of neck metastases upon the initial 
presentation is high, and may be the first sign of the disease 
in 44% to 57% of cases. Bilaterally involved neck lymph 
nodes are found in 50% of cases of undifferentiated carci-
nomas.8 A study of over 5,000 nasopharyngeal carcinoma 
patients showed that 29% had distance metastases and 17% 
of these presented lesions exclusively in distant sites.9
The initial treatment of choice is radiotherapy for 
tumors at early stages, and radiotherapy with chemothe-
rapy for tumors at advanced stages.10,11 Salvage surgery is 
done for the removal of large neck metastases. Salvage 
surgery in persistent primary tumors or recurring tumors 
is rarely indicated.
The purpose of this study was to assess the oncolo-
gical results of treating nasopharyngeal carcinomas during 
a 20-year period in a reference head and neck unit.
SERIES AND METHOD
This was a retrospective study that surveyed the 
medical files of 46 patients diagnosed histopathologically 
with undifferentiated nasopharyngeal carcinomas betwe-
en January 1978 and August 2000. The Research Ethics 
Committee of the institution approved the study (number 
550).
Inclusion criteria were patients with untreated dise-
ase, a confirmed histopathological diagnosis, absence of 
other synchronic neoplasms, absence of distance metasta-
ses upon the initial presentation, and initial therapy with 
curative intent. Between 1978 and 1985 undifferentiated 
carcinomas were diagnosed by histopathology, because 
immunohistochemical testing only became available at the 
institution from 1985 onwards.
The diagnosis of disease was made based on locore-
gional examination and exams such as nasofibrolaryngos-
copy and computed tomography of the face. The definite 
diagnosis of all cases of undifferentiated nasopharyngeal 
carcinomas was made by the pathological examination 
(HE staining) and immunohistochemistry of biopsies of 
nasopharyngeal lesions, taken by posterior rhinoscopy or 
nasosinusal endoscopy.
Teletherapy (cobalt unit and linear accelerator) was 
used for radiotherapy. The radiation dose ranged from 65 
to 75Gy on the primary tumor, divided into 1.8 Gy/day, 
five days a week. Neck lymph node chains received at 
least 45 Gy to 50 Gy.
Simultaneous chemotherapy was done with cispla-
tin (CDDP), 100 mg/m2/week, infused intravenously in 
one hour. Chemotherapy was given by the arterial route 
in one case.
The following variables were assessed: age of 
onset of disease, race, clinical presentation at the time 
of the diagnosis, duration of the clinical history between 
the first symptom or sign and the first visit to a specialist, 
the initial therapy, local and regional recurrences, and 
distance metastases.
RESULTS
The age of patients treated for undifferentiated naso-
pharyngeal carcinomas ranged from 14 to 78 years (mean 
46 years). There were 35 male patients (76%) and 11 female 
patients (23%). All patients were either Caucasian or mixed 
color/black. There were no patients of Asian origin.
The mean time elapsed between the first symptoms 
and the first visit to a specialist was seven months (1 to 
48 months). There were 47% smokers and 33% users of 
alcoholic beverages.
The most commonly reported symptoms were the 
presence of a lump in the throat (34 patients), followed by 
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nasal bleeding (10 patients), nose block (seven patients), 
and pain and weight loss (three patients).
Clinical staging was based on the International Tu-
mor Classification (AJC-UICC); all 46 patients were restaged 
according to the latest revision done in 2002. Relative to 
the primary tumor, 10 cases were T1; 12 cases were T2; 
eight cases were T3, and 16 cases were T4. Relative to 
neck metastatic lymph nodes, five patients were N0, seven 
patients were N1, nine patients were N2, and 25 patients 
were N3. Clinical staging (CS) showed that no patient was 
EC I or II, 16 patients were EC III, and 30 patients were 
EC IV. The locoregional exam showed that 13 patients 
(28.2%) presented lesions on the nasopharyngeal roof. In 
24 patients (52.1%), lesions were on the lateral walls. In 
nine patients (19.5%), the primary lesion was not located 
in the medical examination, being diagnosed by image 
exams.
The physical examination suggested an advanced 
primary tumor with cranial base or intracranial invasion in 
seven patients (15.2%). Paralysis of the 6th cranial nerve 
was seen in three patients (6.5%); paralysis of the 9th cra-
nial nerve was seen in two patients (4.3%); and paralysis 
of the 10th cranial nerve was seen in two patients (4.3%). 
There was no paralysis in more than one cranial never in 
these seven patients.
Therapy in all patients was conventional external 
radiotherapy. Concomitant chemotherapy was done in six 
patients (13%). Chemotherapy was given by the intra-arte-
rial route in one patient (16.6%); the remaining five patients 
(83.4%) received systemic intravenous chemotherapy.
The radiotherapy dose on the primary tumor ran-
ged from 60 to 70 Gy; the radiotherapy dose on neck 
lymph node chains ranged from 34 to 50 Gy. An extra 
dose (boost) was done postoperatively on the dissected 
surgical bed in three of four patients that underwent neck 
salvage surgery.
Follow-up was done for 27 (58.7%) of 46 patients. 
Of these 27 patients, four (14.8%) underwent neck salva-
ge surgery due to persistent or recurrent palpable neck 
lymph nodes.
Distance metastases were diagnosed in seven pa-
tients (25.9%) during a 296 month follow-up period. There 
was locoregional control of the disease and involvement 
of the brain, bones, lungs and skin.
Of the 27 patients that were followed-up after the 
initial treatment, 52% were alive and disease-free at three 
years. The disease-free survival rate was 52% (Figure 1).
DISCUSSION
According to the World Health Organization, naso-
pharyngeal carcinomas may be divided into three types, 
as follows: type 1 - epidermoid carcinomas, which occurs 
mostly in adults; type 2 - non-keratinized carcinomas; and 
type 3 - undifferentiated carcinomas. Type 1 occurs in less 
than 5% of cases in endemic areas, and in 25% of patients 
in non-endemic areas. Type 1 is also the least sensitive to 
radiotherapy; its prognosis is the worst.8
In our study most of the patients were in the fifth 
decade of life. There was no bimodal distribution (a first 
peak in adolescents and young adults). Race was a second 
variation compared to the literature; most of the patients 
were Caucasian, and there were no patients of Asian 
origin.12,13 These findings coincide with those of the Na-
tional Cancer Institute (USA), showing a higher incidence 
of nasopharyngeal carcinomas in young adult Caucasians 
and Afro-Americans compared to Asian patients.14
Tobacco and alcohol are relevant etiological factors 
in upper digestive airways. Undifferentiated nasopharyn-
geal malignancies, however, are less affected by these 
substances, which are not considered etiological in these 
cases.15
Radiotherapy and chemotherapy are the preferred 
therapies in nasopharyngeal carcinomas. Radiotherapy 
is the main treatment in initial tumors. Chemotherapy is 
added in cases with advanced tumors.10,16
Computed tomography and magnetic resonance 
imaging currently have a significant role when planning 
radiotherapy for nasopharyngeal tumors. A study of 275 
magnetic resonance exams showed that there was exten-
sion of metastases to the retropharynx in 63.6% of cases,17 
which is relevant when planning therapy.
The side effects of radiotherapy have decreased with 
the advent of other forms of irradiation (brachytherapy 
and stereotaxic radiotherapy) compared to conventional 
external radiotherapy. The most frequent side effects are 
xerostomy, otitis media, trismus and severe neck fibro-
sis.18
A randomized study of 229 patients with advanced 
stage tumors showed that radiotherapy alone or with 
chemotherapy did not improve local and regional control 
indices.19 Another randomized trial from the Intergroup 
Study 0099 demonstrated improved disease remission rates 
Figure 1. Distribution of disease-free survival of patients with undiffe-
rentiated nasopharyngeal carcinomas.
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by using chemotherapy with radiotherapy in advanced 
stage tumors; in this study, 3-year disease-free survival 
was 69% compared to 24% when treated with radiothe-
rapy alone.10
The Asian Oceanian Clinical Oncology Association 
found no benefits in using neoadjuvante chemotherapy 
with radiotherapy in advanced nasopharyngeal carcino-
mas. They did find a lower incidence of local and regional 
recurrences, but no change in the disease-free survival.20
The literature on control of this disease presents 
mixed results. The first published studies had control rates 
of 87% in T1, 94% in T2, 68% in T3, and 44% in T4 cases 
relative to the primary tumor.21 Later papers showed im-
proved control rates for advanced tumors, with 73% and 
100% in T3, and 71% and 63% in T4.22,23 For the N stage, 
disease control rates are similar in a number of studies, 
reaching 92% and 90% for N0, 87% and 88% for N1, and 
89% and 82% for N3.22,23
The incidence of local recurrence ranges from 18% 
to 58%. Therapy consists of reirradiation or salvage surgery, 
the choice of which remains controversial. Reirradiation 
implies in more complications such as cerebral necrosis, 
hypothalamic-pituitary failure, deafness, retinopathy, trans-
verse actinic myelitis and cranial nerve dysfunction. There 
have been fewer complications by using brachytherapy 
and stereotaxic radiotherapy. Control of local recurrence 
with a second round of radiotherapy has been reported 
in 10% to 30% of cases.24
Regional recurrence rates vary from 8% to 34% of 
cases, similar to the cases of lymph node disease persis-
tence at the end of therapy. In these cases, salvage neck 
dissection is the main form of treatment; success rates reach 
66% of cases. Even with regional disease control, patients 
tend to course with distance metastases.8,23
Neck dissection following the initial therapy used 
to be recommended in all cases of pre-radiotherapy ex-
tensive lymph node disease.25 In a series with 27 patients 
that underwent programmed neck dissection, all cases 
had positive lymph nodes in pathology; 84% of cases had 
extracapsular rupture.
The incidence of hematogenic metastases is high; 
they commonly occur following locoregional disease 
control. Metastases at a distance arise in 5% to 10% of 
patients upon the diagnosis. Frequent sites include the 
lungs, bones and liver.26 A study of 900 patients demons-
trated metastases at a distance in 22.2% of cases during the 
follow-up period of patients that had local and regional 
disease control.27
The treatment of choice in our unit is radiotherapy 
alone in stages I and II, and radiotherapy with chemothe-
rapy in stages III and IV. In this paper only six patients 
were also treated with chemotherapy in advanced disease. 
During the timeframe of this study, radiochemotherapy 
for nasopharyngeal carcinomas in clinical stages III and 
IV was recommended as the ideal treatment; this measu-
re eventually became the therapeutic guideline. In cases 
with large unilateral or bilateral neck metastases, in which 
planning radiotherapy is difficult, neoadjuvante chemo-
therapy is used from 1 to 3 cycles to reduce the size of 
such metastases, after which radiochemotherapy is done. 
The indication of neoadjuvante chemotherapy is based 
on some papers in the literature that have demonstrated 
its benefits; in such cases, toxicity is low and there is an 
increase in disease-free survival.28-29
Neck surgery is done if lymph nodes persist, if 
there are large metastases with probable extracapsular 
extravasation that responded to therapy with complete 
clinical remission, in salvage of cervical lymph nodes 
(especially in N3 cases) and in salvage neck dissection 
following recurrences.
CONCLUSION
The distribution of undifferentiated carcinoma did 
not follow a bimodal distribution per age group. All of 
the treated patients were in advanced clinical stages (III 
and IV), and had a 52% disease-free survival rate at three 
years.
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